Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Sichuan Real&Best Biotech Co. Ltd. currently has 2 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are being reviewed by 2 distinct examiners, which introduces multiple perspectives into the prosecution of the company's biotech innovations. The involvement of 2 distinct art units further indicates that the pending applications are categorized into different technical specialties within the biotechnology sector.
The workload is evenly split, with the busiest examiner, MOEHLMAN, ANDREW TERRY, managing 1 busiest examiner pending action. Since there are a matching number of distinct examiners for the 2 pending office actions, each examiner is responsible for an equal portion of the current pending volume. The presence of 2 distinct art units requires the company to adapt its strategy to the specific guidelines of different examination groups while addressing the individual styles of the assigned examiners. This distribution suggests a diverse range of technical challenges for the pending office actions.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MOEHLMAN, ANDREW TERRY | 1 | 67.0% | +59.7% |
| DABKOWSKI, ERINNE R | 1 | 55.8% | +68.7% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18649917 | ENGINEERED ALPHA-GALACTOSIDASE A (A-GAL A) PEPTIDES AND FUNCTIONAL VARIANTS THEREOF AND ASSOCIATED METHODS OF TREATING FABRY DISEASE | MOEHLMAN, ANDREW TERRY | — |
| 17774450 | Engineered Human FVIII with Enhanced Secretion Ability and Clotting Activity | DABKOWSKI, ERINNE R | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18649917 | ENGINEERED ALPHA-GALACTOSIDASE A (A-GAL A) PEPTIDES AND FUNCTIONAL VARIANTS THEREOF AND ASSOCIATED METHODS OF TREATING FABRY DISEASE | MOEHLMAN, ANDREW TERRY | — |
| 17774450 | Engineered Human FVIII with Enhanced Secretion Ability and Clotting Activity | DABKOWSKI, ERINNE R | — |
| Art Unit | Apps |
|---|---|
| 1655 | 1 |
| 1654 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18649917 | ENGINEERED ALPHA-GALACTOSIDASE A (A-GAL A) PEPTIDES AND FUNCTIONAL VARIANTS THEREOF AND ASSOCIATED METHODS OF TREATING FABRY DISEASE | MOEHLMAN, ANDREW TERRY | 1655 | §101§102§103§112 | Non-Final OA | — | Pending | Apr 29, 2024 |
| 17774450 | Engineered Human FVIII with Enhanced Secretion Ability and Clotting Activity | DABKOWSKI, ERINNE R | 1654 | §102§112 | Non-Final OA | — | Pending | May 04, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialSichuan Real&Best Biotech Co. Ltd. has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Andrew Terry Moehlman has the most, with 1 of Sichuan Real&Best Biotech Co. Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
